330 related articles for article (PubMed ID: 17692344)
21. The cannabinoid receptor CB₁ inverse agonist AM251 potentiates the anxiogenic activity of urocortin I in the basolateral amygdala.
Dono LM; Currie PJ
Neuropharmacology; 2012 Jan; 62(1):192-9. PubMed ID: 21736884
[TBL] [Abstract][Full Text] [Related]
22. Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift?
Caberlotto L; Rimondini R; Hansson A; Eriksson S; Heilig M
Neuropsychopharmacology; 2004 Jan; 29(1):15-22. PubMed ID: 12968131
[TBL] [Abstract][Full Text] [Related]
23. Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission.
Mikics E; Vas J; Aliczki M; Halasz J; Haller J
Behav Pharmacol; 2009 May; 20(3):265-72. PubMed ID: 19421027
[TBL] [Abstract][Full Text] [Related]
24. Effect of intra-amygdala injection of nicotine and GABA receptor agents on anxiety-like behaviour in rats.
Zarrindast MR; Solati J; Oryan S; Parivar K
Pharmacology; 2008; 82(4):276-84. PubMed ID: 18849647
[TBL] [Abstract][Full Text] [Related]
25. The effects of histaminergic agents in the ventral hippocampus of rats in the plus-maze test of anxiety-like behaviours.
Rostami P; Hajizadeh-Moghaddam A; Zarrindast MR
Physiol Behav; 2006 May; 87(5):891-6. PubMed ID: 16600315
[TBL] [Abstract][Full Text] [Related]
26. Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats.
Aguiar DC; Terzian AL; Guimarães FS; Moreira FA
Psychopharmacology (Berl); 2009 Aug; 205(2):217-25. PubMed ID: 19387617
[TBL] [Abstract][Full Text] [Related]
27. Differential role of the basolateral amygdala 5-HT3 and 5-HT4 serotonin receptors upon ACPA-induced anxiolytic-like behaviors and emotional memory deficit in mice.
Chegini HR; Nasehi M; Zarrindast MR
Behav Brain Res; 2014 Mar; 261():114-26. PubMed ID: 24333573
[TBL] [Abstract][Full Text] [Related]
28. Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain.
Thiemann G; Watt CA; Ledent C; Molleman A; Hasenöhrl RU
Behav Brain Res; 2009 Jun; 200(1):60-7. PubMed ID: 19162082
[TBL] [Abstract][Full Text] [Related]
29. The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze.
Takahashi RN; Pamplona FA; Fernandes MS
Neurosci Lett; 2005 Jun; 380(3):270-5. PubMed ID: 15862900
[TBL] [Abstract][Full Text] [Related]
30. Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety like behaviours in rats using the elevated plus-maze test.
Roohbakhsh A; Moghaddam AH; Massoudi R; Zarrindast MR
Clin Exp Pharmacol Physiol; 2007 Mar; 34(3):223-9. PubMed ID: 17250643
[TBL] [Abstract][Full Text] [Related]
31. The cannabinoid CB1 receptor is involved in the anxiolytic, sedative and amnesic actions of benzodiazepines.
García-Gutiérrez MS; Manzanares J
J Psychopharmacol; 2010 May; 24(5):757-65. PubMed ID: 19825899
[TBL] [Abstract][Full Text] [Related]
32. Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study.
Acquas E; Pisanu A; Marrocu P; Goldberg SR; Di Chiara G
Eur J Pharmacol; 2001 May; 419(2-3):155-61. PubMed ID: 11426837
[TBL] [Abstract][Full Text] [Related]
33. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
[TBL] [Abstract][Full Text] [Related]
34. Effects of environmental enrichment on anxiety responses, spatial memory and cytochrome c oxidase activity in adult rats.
Sampedro-Piquero P; Zancada-Menendez C; Begega A; Rubio S; Arias JL
Brain Res Bull; 2013 Sep; 98():1-9. PubMed ID: 23831916
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of CB1 receptor agonism in behavioural tests of unconditioned and conditioned fear in adult male rats.
Simone JJ; Green MR; Hodges TE; McCormick CM
Behav Brain Res; 2015 Feb; 279():9-16. PubMed ID: 25446756
[TBL] [Abstract][Full Text] [Related]
36. Involvement of prelimbic 5-HT
Du CX; Guo Y; Zhang QJ; Zhang J; Lv SX; Liu J
Neurol Res; 2018 Oct; 40(10):847-855. PubMed ID: 29989483
[TBL] [Abstract][Full Text] [Related]
37. Role of ventral hippocampal GABA(A) and NMDA receptors in the anxiolytic effect of carbamazepine in rats using the elevated plus maze test.
Rezvanfard M; Zarrindast MR; Bina P
Pharmacology; 2009; 84(6):356-66. PubMed ID: 19907194
[TBL] [Abstract][Full Text] [Related]
38. Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1- and non-CB1-mediated actions.
Pistis M; Perra S; Pillolla G; Melis M; Gessa GL; Muntoni AL
Neuropharmacology; 2004 Jan; 46(1):115-25. PubMed ID: 14654103
[TBL] [Abstract][Full Text] [Related]
39. Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists.
Hill MN; Froese LM; Morrish AC; Sun JC; Floresco SB
Psychopharmacology (Berl); 2006 Aug; 187(2):245-59. PubMed ID: 16752140
[TBL] [Abstract][Full Text] [Related]
40. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
